Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;41(2):259-265.
doi: 10.1097/IAE.0000000000002855.

ASSOCIATION OF VITREORETINAL LYMPHOMA WITH SYSTEMIC LYMPHOMA

Arman Mashayekhi  1 , Lauren A Dalvin, Li-Anne S Lim, David Ancona-Lezama, Mehdi Mazloumi, Michael Chang, Carol L Shields, Jerry A Shields
Affiliations

ASSOCIATION OF VITREORETINAL LYMPHOMA WITH SYSTEMIC LYMPHOMA

Arman Mashayekhi et al. Retina. .

Abstract

Purpose: To determine the association between vitreoretinal lymphoma and systemic lymphoma (SL).

Methods: Single-center retrospective review of medical records.

Results: Of 95 patients with vitreoretinal lymphoma, 18 (19%) had associated SL (SL group) and 77 (81%) were not associated with SL (no SL group). The most common sites of SL were skin (n = 5), testis (n = 2), liver and breast (n = 2), and others (n = 9). A comparison (SL group vs. [vs.] no SL group) revealed no difference in demographic or ocular findings at initial visit. In the SL group, SL occurred before the onset of ocular symptoms in 14 (78%) patients with mean interval of 86 months (median 61, range 5-286 months) or after ocular symptoms in 4 (22%) patients with mean interval of 19 months (median 12, range 7-44 months). A comparison revealed no difference in overall frequency of pre-existing or eventual central nervous SL (50% vs. 53%, P = 0.99); however, the SL group demonstrated central nervous SL more often after onset of ocular symptoms (78% vs. 17%, P = 0.001). A comparison found no difference in treatment methods, response of vitreoretinal lymphoma to treatment, final visual outcome, or death rate.

Conclusion: We found 19% of patients with vitreoretinal lymphoma demonstrate related SL, and there was no difference in demographics, clinical features, or response to treatment, compared to those not associated with SL.

PubMed Disclaimer

References

    1. Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol 2014;59:503–516.
    1. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011;16:1589–1599.
    1. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol 2008;36:564–578.
    1. Hattenhauer MG, Pach JM. Ocular lymphoma in a patient with chronic lymphocytic leukemia. Am J Ophthalmol 1996;122:266–268.
    1. Williams GC, Holz E, Lee AG, Font RL. T-cell lymphoproliferative disorder of vitreous associated with mycosis fungoides. Arch Ophthalmol 2000;118:278–280.

LinkOut - more resources